Document text
Principal Investigator: James D. Bryers
Organization: UNIVERSITY OF WASHINGTON
Fiscal Year: 2022
Award: $540,184
Funding agency: National Institute of Allergy and Infectious Diseases
While Staphylococcus aureus (SA) commonly asymptomatically colonizes the skin and nose of healthy
humans, severe disease can result from infection of the blood, bone, skin, and lungs, as well as sites of
catheters and prosthetic devices. With currently approved therapy, about one-third of patients diagnosed with
SA bacteremia succumb, accounting for more annual deaths than HIV, tuberculosis, and viral hepatitis
combined. This R01 will develop an injectable vaccine depot comprising: (a) previously published cationic
polymers to condense and charge neutralize anionic self-replicating mRNA (SR-mRNA) vaccines into
nanometer-sized particles (i.e., “polyplexes”) that are then incorporated within (b) our recently reported
injectable biodegradable gel of N-succinyl-chitosan (S-CS) and oxidized alginate (O-Alg). Ultimately, the
temporary CS-Alg depots completely biodegrade into non-toxic by-products that are eliminated. This project
will generate a self-immunizing biomaterials technology that is applied ONCE that is superior in immunization
versus repeated systemic bolus injections.
Terms: <3-D><3-Dimensional><3D><7S Gamma Globulin><Ab response><Accounting><Adjuvant><Affinity><Alginates><Antibiotic Agents><Antibiotic Drugs><Antibiotics><Antibodies><Antibody Formation><Antibody Production><Antibody titer measurement><Antigen Targeting><Antigens><B blood cells><B cell><B cells><B-Cells><B-Lymphocytes><B-cell><Bacteremia><Bacteria><Bacterial Adhesins><Biocompatible Materials><Biomaterials><Bolus><Bolus Infusion><Bone Infection><COVID><Catheters><Cations><Cause of Death><Cell Communication and Signaling><Cell Signaling><Cell secretion><Cellular Secretion><Cessation of life><Charge><Chitosan><CoV disease><DNA><Data><Death><Dendritic Cells><Deoxyribonucleic Acid><Diagnosis><Disease><Disorder><Dose><Exhibits><Gamma interferon><Gel><Genes><Glycans><HIV/Mtb><HIV/TB><HIV/mycobacterium tuberculosis><HIV/tuberculosis><Hospital Infections><Hospital acquired infection><Human><Hydrogels><IFN-Gamma><IFN-g><IFN-γ><IFNG><IFNγ><IgG><Immune Interferon><Immune response><Immunity><Immunization><Immunize><Immunoglobulin G><Immunologic Sensitization><Immunologic Stimulation><Immunological Sensitization><Immunological Stimulation><Immunological response><Immunostimulation><Implant><In Vitro><Individual><Infection><Infectious Skin Diseases><Injectable><Injections><Interferon Gamma><Interferon Type II><Interferon-gamma><Intracellular Communication and Signaling><Intravenous><Kinetics><Liquid substance><Lung infections><M. tuberculosis/HIV><MRSA><Medical Care Costs><Medical Device><Membrane><Memory B Cell><Memory B-Lymphocyte><Messenger RNA><Methicillin Resistance><Methicillin Resistant S Aureus><Methicillin Resistant S. Aureus><Mice><Mice Mammals><Microbial Biofilms><Miscellaneous Antibiotic><Modeling><Modern Man><Murine><Mus><Nasal><Nasal Passages Nose><Nose><Nosocomial Infections><Osteomyelitis><Oxides><Particle Size><Pathogenicity Factors><Patients><Peptides><Persons><Phase><Poliglusam><Polymers><Polysaccharides><Program Development><Prosthesis><Prosthetic device><Prosthetics><Protein Subunits><Publishing><RNA vaccine><RNA-based vaccine><Reaction><Reporting><Resistance to methicillin><Resistant to methicillin><Respiratory System, Nose, Nasal Passages><S aureus><S epidermidis><S. aureus><S. aureus infection><S. epidermidis><Schiff Bases><Sepsis><Series><Signal Transduction><Signal Transduction Systems><Signaling><Site><Skin colonization><Splenocyte><Staph aureus><Staph aureus infection><Staphylococcus aureus><Staphylococcus aureus infection><Staphylococcus epidermidis><Subunit Vaccines><Survival Rate><Syringes><System><T cell response><T-Cells><T-Lymphocyte><Technology><Text><United States><VRSA><Vaccines><Vancomycin><Vancomycin resistant S. aureus><Vancomycin resistant Staph aureus><Vancomycin-resistant S. aureus><Vancomycin-resistant S.aureus><Vancomycin-resistant Staphylococcus aureus><Veiled Cells><Viral hepatitis><Virulence Factors><Work><adhesin><antibody biosynthesis><antibody titering><bacteraemia><bacterial sepsis><biofilm><biological material><biological signal transduction><blood infection><bloodstream infection><corona virus disease><coronavirus disease><cross-link><crosslink><cutaneous infection><deliver vaccines><design><designing><develop a vaccine><develop vaccines><development of a vaccine><extracellular><fluid><hepatitis virus infection><host response><immune system response><immunogen><immunoglobulin biosynthesis><immunoresponse><in vivo><infected skin><infected with S. aureus><infected with Staph aureus><infected with Staphylococcus aureus><institutional infection><lFN-Gamma><liquid><mRNA><mRNA vaccine><mRNA-based vaccine><medical costs><medical implant><membrane structure><methicillin resistant><methicillin resistant Staphylococcus aureus><methicillin-resistant S. aureus><nano meter scale><nano meter sized><nano particle><nano scale><nano-sized particle><nanometer scale><nanometer sized><nanoparticle><nanoscale><nanosized particle><new drug treatments><new drugs><new therapeutics><new therapy><next generation therapeutics><novel><novel drug treatments><novel drugs><novel therapeutics><novel therapy><outcome following vaccination><outcome following vaccine><plasmid vaccine><porous hydrogel><pre-clinical research><preclinical research><prevent><preventing><pulmonary infections><response><result following vaccination><result following vaccine><scaffold><scaffolding><skin infection><three dimensional><thymus derived lymphocyte><vaccination outcome><vaccination result><vaccine delivery><vaccine development><vaccine outcome><vaccine result><vector><vector vaccine>